Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma
A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment.
No hay comentarios:
Publicar un comentario